Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Just Group Jumps 23% On Regulatory Decision

Mon, 10th Dec 2018 10:59

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------NMC Health, up 1.3%. The UAE-based private healthcare operator reiterated its previous annual earnings guidance, citing supportive industry dynamics and continued positive operational developments. For 2018, NMC Health said it expects to record 24% year-on-year growth in total revenue, with organic revenue growth of 15%. Total revenue in 2017 stood at USD1.60 billion, with organic growth have contributed roughly 16% that year. A 24% increase suggests 2018 revenue will be just short of USD2 billion. Earnings before interest, tax, depreciation and amortisation for 2018 is predicted to total USD480 million, up 36% from USD353.4 million a year ago. NMC also said it has secured a contract to manage a hospital in Seychelles.----------Informa, up 1.1%. JPMorgan upgraded the exhibitions and business information group to Overweight from Neutral.----------FTSE 100 - LOSERS----------SSE, down 3.0%. Deutsche Bank downgraded the energy supplier to Hold from Buy.----------Barratt Developments, down 1.9%, Taylor Wimpey, down 1.2%, Berkeley Group, down 0.7%. Peel Hunt downgraded Barratt and Berkeley to Add from Buy and cut Taylor Wimpey to Hold from Add. ----------FTSE 250 - WINNERS----------Just Group, up 23%. The life insurer said the UK Prudential Regulation Authority's policy statement on equity release mortgages being held to back annuity liabilities will not affect its business pricing. Just Group said it has already aligned its new business pricing with the expected capital requirements from the PRA's consultation paper. Monday's policy statement follows a three-month consultation following the release of the regulator's consultation paper on equity release mortgages. Just Group, in particular, said it "welcomes" the confirmation that transitional relief will remain available for pre-2016 business. Just Group said that, following the release of the policy statement, the minimum deferment rate for allowing no negative equity risks will be 1% with a 13% property volatility rate - which is towards the lower end of the range considered in the consultation paper. The financial services regulator confirmed it has no plans to apply effective value tests to other assets.----------Spire Healthcare, up 9.5%. Morgan Stanley raised the private healthcare company to Overweight from Equal Weight. ----------FTSE 250 - LOSERS----------Thomas Cook, down 8.7% at 28.20p. UBS cut its price target on the travel agent to 34p from 60p and reiterated its Neutral rating on the stock. Thomas Cook will be demoted from the FTSE 250 as part of the FTSE Russell quarterly review changes that come into effect later this month. ----------Crest Nicholson, down 6.0%. Peel Hunt downgraded the housebuilder to Reduce from Hold. ----------OTHER MAIN MARKET AND AIM - WINNERS----------ValiRX, up 27%. The biotechnology firm said an independent analysis of VAL201 showed a positive effect on patients with hormone-sensitive and hormone-resistant prostate cancer. The study was undertaken using a non-parametric approach - both the well-established Friedman test and the most up-to-date statistical method, repeated measures multiple correlation analysis. This analysis revealed that volunteers treated with VAL201 displayed a "statistically significant" correlation for reductions over time in the amount of testosterone and prostate specific antigen, which stimulate the progression of prostate cancer.----------Hollywood Bowl, up 7.5%. The ten-pin bowling operator announced a special dividend for the second straight year as it reported a double-digit rise in annual profit. In the financial year ended September 30, the ten-pin bowling centre operator increased its pretax profit 13% to GBP23.9 million from GBP21.1 million last year. Revenue increased 5.7% to GBP120.5 million from GB114.0 million the year before. Hollywood Bowl reported a like-for-like revenue increase of 1.8% in the period. The company hiked its total dividend by 17% to 10.59 pence from 9.08p paid out last year. Hollywood Bowl's higher total dividend included a 30% increase in special dividend to 4.33p from 3.33p. The company opened two new centres during the period, in Dagenham and Yeovil, while closing one in Gravesend, taking its total to 58.----------OTHER MAIN MARKET AND AIM - LOSERS----------Interserve, down 51%. The outsourcer said it secured GBP25 million contract from Cwm Taf University Health Board with works commencing in December, providing some positive news a day after it admitted shareholders face "material dilution" from refinancing plan being discussed with creditors. On Saturday, The Financial Times said Interserve's shareholders could lose everything under the terms of a rescue finance plan being discussed between Interserve and creditors. Under the terms of the proposed plan, banks and other debt holders would take a significant loss as part of a debt-for-equity swap, while public shareholders would be virtually wiped out, the newspaper said. On Sunday, Interserve confirmed its lenders are engaged in constructive discussions regarding the agreement and implementation of a deleveraging plan, which it said would deliver a strong balance sheet.----------Photo-Me International, down 10%. The photo booth operator said its profit dropped in the first half of its current financial year due to the lower machine sales in the UK. Photo-Me said pretax profit declined 13% to GBP26.0 million in the six months to the end of October from GBP32.9 million reported for the same period a year earlier, as revenue slipped to GBP119.8 million from GBP122.2 million. The company said revenue was hurt by restructuring in Photo-Me Retail, which resulted in GBP5.3 million reduction in revenue. Excluding that, underlying revenue was up 2.5%. The company said pretax profit took a hit from lower B2B revenue and machine sales activity, especially in the UK, Photo-Me noted. Photo-Me declared an interim dividend of 3.71 pence a share, unchanged year-on-year. ----------

More News
20 Jun 2019 09:54

ValiRx secures 'substantial amendment' to VAL201 clinical trials

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

Read more
13 Jun 2019 11:07

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.Shares in ValiRx a 31%

Read more
10 Jun 2019 09:50

ValiRx In Discussions With Investor To End Subscription Agreement (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Monday confirmed it is in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement.Shares in the clinical

Read more
5 Jun 2019 10:54

ValiRx Convertible Bond Talks In Advanced Stage; Plans Open Offer (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Wednesday said it is in advanced discussions with European High Growth Opportunities SF to enter a new convertible bond facility and is planning an open in a

Read more
31 May 2019 12:04

ValiRx Extends Talks With Investor Over New Convertible Bond (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has extended the deadline to enter into a new convertible bond with European High Growth Opportunities SF to July 1.The cancer life was

Read more
29 May 2019 10:41

ValiRx Annual Loss Widens On Higher Costs And Fair Value Losses

LONDON (Alliance News) - ValiRx PLC on Wednesday reported a widened annual loss due to higher costs and losses on the fair value of financial assets.For 2018 the life sciences company, on a

Read more
29 May 2019 10:19

ValiRx losses widen as it continues to progress drug development

(Sharecast News) - Life science company ValiRx reported a loss before income tax of £4.83m in its final results on Wednesday, widening from the £3.55m loss it posted a year earlier.

Read more
2 May 2019 15:21

ValiRx Partners With Alpha Blue Ocean And Buys IP Assets Of FIT Bio

LONDON (Alliance News) - ValiRx PLC on Thursday said it has agreed to acquire the IP assets of FIT Bio for EUR5,000 and establish a genetic therapeutic and diagnostic-based joint venture with Blue

Read more
2 May 2019 09:51

ValiRx acquires IP of failed firm FIT Biotech, forms joint venture

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acquisition of the global granted patents and intellectual property assets of FIT Biotech for a nominal sum on Thursday.

Read more
26 Apr 2019 14:54

ValiRx To Raise GBP1 Million Under Deal With European High Growth (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has entered into a GBP1.3 million subscription agreement with European High Growth Opportunities SF.The stock was trading 17% lower on

Read more
26 Mar 2019 10:22

ValiRx Notes ValiSeek Co-Financing Deals For VAL401 Cancer Drug

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Tuesday said ValiSeek has secured letters of intent from two companies to co-finance the development of cancer drug VAL401.Shares a

Read more
21 Mar 2019 09:53

ValiRx Notes Encouraging Performance Of VAL201 In Cancer Trial

LONDON (Alliance News) - ValiRx PLC on Thursday said an interim inspection of its VAL201 early phase cancer trial shows the drug is performing as predicted.Shares in ValiRx were up 13% at a

Read more
21 Feb 2019 12:46

ValiRx Raises GBP500,000 Through Placing To Advance Clinical Trials (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Thursday raised GBP500,000 through a share placing to expand its clinical trial of VAL201, as well as the VAL301 and VAL101 programmes.ValiRx issued a

Read more
31 Jan 2019 13:37

ValiRx Secures Patent For VAL301 Compound In Russia And China

LONDON (Alliance News) - ValiRx PLC on Thursday said it has been granted a patent allowance for its therapeutic compound VAL301 in both Russia and China.The clinical stage biotechnology has

Read more
31 Jan 2019 10:08

ValiRx allowed patents for VAL401 in Russia and China

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.